Treatment of patients with COVID-19-associated immune thrombocytopenia in real clinical practice

Author:

Voytsekhovskiy V. V.1,Esenina T. V.2,Krivutsa V. A.1,Filatova E. A.2,Fedorova N. A.2

Affiliation:

1. Amur State Medical Academy

2. Amur Regional Clinical Hospital

Abstract

Aim. Demonstration of three clinical cases of immune thrombocytopenic purpura (ITP) that developed during the pandemic of a novel coronavirus infection (COVID-19) from the personal practice of the authors.Materials and methods. A brief review of the literature on the diagnosis and differential diagnosis of COVID-19-associated ITP is presented. Three clinical observations of this pathology are given.Results. In two situations, thrombocytopenia developed after severe COVID-19-associated pneumonia. In one case, ITP was diagnosed after a viral infection; PCR test for COVID19 was negative. A young patient without comorbidities with severe thrombocytopenia and hemorrhagic syndrome was treated with glucocorticoids and thrombopoietin receptor agonists (TPO-RAs). After achieving remission, glucocorticoids were first discontinued, and then TPO-RAs. In elderly patients with a serious comorbid pathology, glucocorticoids were prescribed for a short time, and remission was achieved with TPO-RAs.Conclusion. The choice of therapy for ITP that developed during the COVID-19 pandemic depends on the clinical situation, the presence or absence of COVID-19 infection, the patient’s somatic status, and the presence of comorbid pathology. TPO-RAs play an important role in the treatment of ITP, including those associated with COVID-19.

Publisher

Far Eastern Scientific Center Of Physiology and Pathology of Respiration

Subject

General Medicine

Reference22 articles.

1. Provan D., Stasi R., Newland A.C., Blanchette V.S., Bolton-Maggs P., Bussel J.B., Chong B.H., Cines D.B., Gernsheimer T.B., Godeau B., Grainger J., Greer I., Hunt B.J., Imbach P.A., Lyons G., McMillan R., Rodeghiero F., Sanz M.A., Tarantino M., Watson S., Young J., Kuter D.J. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115(2):168‒186. https://doi.org/10.1182/blood-2009-06-225565

2. Rodeghiero F., Stasi R., Gernsheimer T., Michel M., Provan D., Arnold D.M., Bussel J.B., Cines D.B., Chong B.H., Cooper N., Godeau B., Lechner K., Mazzucconi M.G., McMillan R., Sanz M.A., Imbach P., Blanchette V., Kühne T., Ruggeri M., George J.N. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113(11):2386‒2393. https://doi.org/10.1182/blood-2008-07-162503

3. Mazurov A.V. [Physiology and pathology of platelets]. Moscow: Litterra; 2011 (in Russian). ISBN: 978-5-42350049-8

4. Melikyan A.L., Pustovaya E.I. [Algorithm for the diagnosis of primary immune thrombocytopenia. In: Savchenko V.G., editor. Algorithms for the diagnosis and treatment of diseases of the blood system (Vol.1)]. Moscow: Praktika; 2018:231–242 (in Russian). ISBN: 978-5-89816-164-4

5. Thota S., Kistangari G., Daw H., Spiro T. Immune thrombocytopenia in adults: an update. Cleve. Clin. J. Med. 2012; 79(9):641‒650. https://doi.org/10.3949/ccjm.79a.11027

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3